Publications - 'B'
Publications 251 - 275 de 850
| Titre | DOI |
|---|---|
|
Between the Megalopolis and the Deep Blue Sky: Challenges of Transport with UAVs in Future Smart Cities Y. Mualla; A. Najjar; S. Galland; C. Nicolle; I.Haman Tchappi; A.U.H. Yasar; K. Framling 2019 |
|
|
Between the war and the peace. Neutrality and international relations, the seventeenth-eighteenth centuries E. Dziembowski 2014 |
10.3917/rhmc.612.0232 |
|
Between yesterday occupied and tomorrow ``liberated''. The consequences of the period 1940-1944 on the French police and police society J.M. Berliere 2021 |
10.20318/hn.2021.5894 |
|
Betweenness Centrality for Networks with Non-Overlapping Community Structure Z. Ghalmane; M.El Hassouni; H. Cherifi 2018 |
|
|
Betweenness Centrality for Networks with Non-Overlapping Community Structure Z. Ghalmane; M.El Hassouni; H. Cherifi 2018 |
|
|
Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI J. Bennouna; S. Hiret; C. Borg; A. Bertaut; O. Bouche; G. Deplanque; E. Francois; T. Conroy; F. Ghiringhelli; D. Guetz; J.F. Seitz; P. Artru; T. Stanbury; S. Charpentier; M. Denis; A. Adenis 2017 |
|
|
Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODI J. Bennouna; S. Hiret; C. Borg; A. Bertaut; O. Bouche; G. Deplanque; E. Francois; T. Conroy; F. Ghiringhelli; D. Guetz; J.F. Seitz; P. Artru; T. Stanbury; S. Charpentier; M. Denis; A. Adenis 2017 |
|
|
Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France J.Y. Pierga; R. Delva; X. Pivot; M. Espie; F. Dalenc; D. Serin; C. Veyret; A. Lortholary; J. Gligorov; K. Joly; J. Hernandez; A.C. Hardy-Bessard 2014 |
10.1684/bdc.2014.2019 |
|
Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group T. Andre; D. Vernerey; S.A. Im; G.M. Bodoky; R. Buzzoni; S. Reingold; F. Rivera; J. McKendrick; W. Scheithauer; R. Geva; G. Fountzilas; W.P. Yong; R. Isaacs; P. Osterlund; J.T. Liang; G.J. Creemers; E. Van Cutsem; D. Cunningham; J. Tabernero; A. de Gramont 2019 |
|
|
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group T. Andre; D. Vernerey; S.A. Im; G. Bodoky; R. Buzzoni; S. Reingold; F. Rivera; J. McKendrick; W. Scheithauer; G. Ravit; G. Fountzilas; W.P. Yong; R. Isaacs; P. Osterlund; J.T. Liang; G.J. Creemers; M. Rakez; E. Van Cutsem; D. Cunningham; J. Tabernero; A. de Gramont 2020 |
10.1016/j.annonc.2019.12.006 |
|
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies L. Salvatore; E. Bria; I. Sperduti; A. Hinke; S. Hegewisch-Becker; T. Aparicio; K. Le Malicot; V. Boige; D. Koeberle; D. Baertschi; D. Dietrich; G. Tortora; D. Arnold 2021 |
10.1016/j.ctrv.2021.102202 |
|
Bevacizumab combined with 1st line chemotherapy in elderly patients (>= 75 years-old) with metastatic colorectal cancer - Interim results according to the chemotherapy regimen (CASSIOPEE) L. Mineur; E. Francois; S. Kim; F. Burki; P. Laplaige; S. Gourgou; F. Rollot-Trad; J. Telliez; S. Gandon; D. Smith 2016 |
10.1093/annonc/mdw370.99 |
|
Bevacizumab Combined with Chemotherapy for Patients with Advanced NSCLC and Brain Metastasis. A French Cohort Study J. Bennouna; L. Falchero; R. Schott; F. Bonnetain; M. Coudert; B.Hadj Yahia; C. Chouaid 2017 |
10.1016/j.jtho.2017.09.463 |
|
Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection F. Ghiringhelli; D. Bichard; S. Limat; V. Lorgis; J. Vincent; C. Borg; J. Berthou; D. Orry; P. Ortega-Deballon; Z. Lakkis; O. Facy; B. Heyd; P. Rat; V. Nerich; S. Ladoire 2014 |
10.1245/s10434-013-3463-y |
|
Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study C. Chouaid; L. Falchero; R. Schott; F. Bonnetain; N. Taguieva-Pioger; J. Bennouna 2017 |
10.1016/j.rmr.2016.05.003 |
|
Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE) J. Bennouna; L. Falchero; R. Schott; F. Bonnetain; M. Coudert; B.Ben Hadj Yahia; C. Chouaid 2018 |
10.1159/000480702 |
|
Bevacizumab Maintenance in Metastatic Colorectal Cancer Reply T. Aparicio; F. Ghiringhelli; V. Boige; K. Le Malicot; J. Taieb; J. Bennouna 2018 |
10.1200/JCO.2018.78.9669 |
|
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) T. Aparicio; F. Ghiringhelli; V. Boige; K. Le Malicot; J. Taieb; O. Bouche; J.M. Phelip; E. Francois; C. Borel; R. Faroux; L. Dahan; S. Jacquot; D. Genet; F. Khemissa; E. Suc; F. Desseigne; P. Texereau; C. Lepage; J. Bennouna; P.R.O.D.I.G.E.9 Investigators 2018 |
10.1200/JCO.2017.75.2931 |
|
Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18-UNICANCER GI). S. Hiret; C. Borg; A. Bertaut; O. Bouche; A. Adenis; G. Deplanque; E. Francois; T. Conroy; F. Ghiringhelli; G.Des Guetz; J.F. Seitz; P. Artru; T. Stanbury; M.G. Denis; J. Bennouna 2016 |
10.1200/JCO.2016.34.15_suppl.3514 |
|
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients M. Caulet; T. Lecomte; O. Bouche; J. Rollin; V. Gouilleux-Gruart; N. Azzopardi; J. Leger; C. Borg; J.Y. Douillard; S. Manfredi; D. Smith; O. Capitain; A. Ferru; D. Moussata; E. Terrebone; G. Paintaud; D. Ternant 2016 |
10.1007/s40262-016-0406-3 |
|
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised G. von Minckwitz; F. Puglisi; J. Cortes; E. Vrdoljak; N. Marschner; C. Zielinski; C. Villanueva; G. Romieu; I. Lang; E. Ciruelos; M. De laurentiis; C. Veyret; S. de Ducla; U. Freudensprung; S. Srock; J. Gligorov 2014 |
10.1016/S1470-2045(14)70439-5 |
|
Bevacizumab plus chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results T. Aparicio; O. Bouche; J. Taieb; E. Maillard; S. Kirscher; P.L. Etienne; R. Faroux; K. Akouz; E. Hajbi; C. Locher; Y. Rinaldi; T. Lecomte; S. Lavau-Denes; M. Baconnier; A. Oden-Gangloff; D. Genet; E. Paillaud; F. Retornaz; E. Francois; L. Bedenne; P.R.O.D.I.G.E.20 Investigators 2018 |
10.1093/annonc/mdx529 |
|
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group A. de Gramont; J. Henriques; B. Baruch; T.W. Kim; M. Martinez-Villacampa; J. Gallego-Plazas; A. Cervantes; K. Shim; D.J. Jonker; V. Guerin-Meyer; L. Mineur; M. Banzi; A. Dewdney; S. Dejthevaporn; H.J. Bloemendal; A.D. Roth; P. Thompson; M. Moehler; A. Aguilar; T. Andre 2019 |
|
|
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group A. de Gramont; J. Henriques; B. Baruch; T.W. Kim; M. Martinez-Villacampa; J. Gallego-Plazas; A. Cervantes; K. Shim; D.J. Jonker; V. Guerin-Meyer; L. Mineur; M. Banzi; A. Dewdney; S. Dejthevaporn; H.J. Bloemendal; A.D. Roth; P. Thompson; M. Moehler; A. Aguilar; T. Andre 2019 |
|
|
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial C. Tournigand; B. Chibaudel; B. Samson; W. Scheithauer; D. Vernerey; P. Mesange; G. Lledo; F. Viret; J.F. Ramee; N. Tubiana-Mathieu; J. Dauba; O. Dupuis; Y. Rinaldi; M. Mabro; N. Aucoin; J. Latreille; F. Bonnetain; C. Louvet; A.K. Larsen; T. Andre; A. de Gramont 2015 |
10.1016/S1470-2045(15)00216-8 |